## PATENT COOPERATION TREATY



## **PCT**

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference E1-A0211P	FOR FURTHER ACT	TION	See Form PCT/IPEA/416		
International application No. PCT/JP2004/000629	International filing date 23 January 2004		Priority date (day/month/year) 24 January 2003 (24.01.2003)		
International Patent Classification (IPC) or national classification and IPC C12N 15/09, C07K 16/28, C12N 5/08, C12P 21/08, C12Q 1/68, 1/02, G01N 33/50, 33/53, A61P 25/00					
Applicant EISAI CO., LTD.					
<ol> <li>This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.</li> </ol>					
2. This REPORT consists of a total of6 sheets, including this cover sheet.  3. This report is also accompanied by ANNEXES, comprising:					
3. This report is also accompanied by ANNEXES, comprising.  a. (sent to the applicant and to the International Bureau) a total of sheets, as follows:					
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).					
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.					
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))  DISC 1, containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).					
4. This report contains indications relating to the following items:					
Box No. I Basis of the	Box No. I Basis of the report				
Box No. II Priority					
	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability				
Roy No. V. Reasoned sta	Box No. IV Lack of unity of invention  Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;				
L	citations and explanations supporting such statement  Box No. VI Certain documents cited				
Box No. VIII Certain obse	Box No. VIII Certain observations on the international application				
Date of submission of the demand		Date of completion	n of this report		
29 July 2004 (29.07	.2004)	27 I	December 2004 (27.12.2004)		
Name and mailing address of the IPEA/JP		Authorized officer			
Facsimile No.		Telephone No.			

Translation

International application No.

PCT/JP2004/000629

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

Box No. 1	I Ba	sis of the report	
1. With re	vise indi	the language, this report is based on the international application in the language in wh cated under this item.	
	This re	port is based on translations from the original language into the following language s language of a translation furnished for the purpose of:	*
	in	ternational search (under Rules 12.3 and 23.1(b))	
	pı	ublication of the international application (under Rule 12.4)	
	in	ternational preliminary examination (under Rules 55.2 and/or 55.3)	
furnisi and ai	hed to ti re not ai	to the elements of the international application, this report is based on (replacement the receiving Office in response to an invitation under Article 14 are referred to in this innexed to this report):	nt sheets which have been report as "originally filed"
=		ernational application as originally filed/furnished	
		cription:	, as originally filed/furnished
	pages	received by this Authority on	_,
	pages* pages*	received by this Authority on	
	the clai	ms:	, as originally filed/furnished
	pages*	, as amended (together with a	any statement) under Article 19
	pages*	The state of the s	
	pages*	received by this Authority on	
	the dra	wings.	_, as originally filed/furnished
	pages*	received by this Authority on	
	pages*	received by this Authority on	
$\square$		ence listing and/or any related table(s) — see Supplemental Box Relating to Sequence Lis	ting.
	a scque	nico histing allows any research	
		the state of the sense lighting of	
3.	The an	nendments have resulted in the cancellation of:	
Ì	<u></u>	he description, pages	
		the claims, Nos.	
		the drawings, sheets/figs	
		the sequence listing (specify):	
		any table(s) related to sequence listing (specify):	
1			
4.	made, (Rule	eport has been established as if (some of) the amendments annexed to this report and since they have been considered to go beyond the disclosure as filed, as indicated 70.2(c)).  the description, pages	listed below had not been in the Supplemental Box
	$\sqcap$	the claims, Nos.	
	==	the drawings, sheets/figs	
	=	the sequence listing (specify):	
		any table(s) related to sequence listing (specify):	
	Ш	any subsect, related to obstacle the Diff.	•
* If ite	em 4 app	olies, some or all of those sheets may be marked "superseded."	
1 _			

PCT/JP2004/000629

laims	1, 3-5, 7, 8	YES
	1, 2 0, 7, 0	
laims	2, 6	NO
Claims	1, 3-5	YES
Claims	2, 6-8	NO
Claims	1-8	YE:
Claims		NO
	laimslaims	laims 1, 3-5 laims 2, 6-8 laims 1-8

2. Citations and explanations (Rule 70.7)

Document 1: WO 99/64608 A1 (Schering AG) December 16, 1999

& EP 1084259 A1 & JP 2002-517253 A

Document 2: WO 01/057194 A2 (Corvas International Inc.) August 9, 2001

& EP 1252300 A2 & US 2003/0119168 A1 & JP 2003-521920 A

Document 3: Eur. J. Biochem., Vol. 267, No. 23, pp 6931-6937 (2000)

Document 4: WO 00/06700 A1 (Layton Bioscience Inc.) February 10, 2000

& EP 1109887 A1

Document 5: US 6277820 B1 (Genentech Inc.) August 21, 2001

#### Claim 2

Based on the descriptions in documents 1-3 cited in the international search report, the invention of claim 2 lacks novelty and an inventive step.

Document 1 describes antibodies to human and murine Corin (equivalent to Lrp4/Corin in the present application); document 2 describes antibodies to the human type II membrane serine protease MTSP (equivalent to Lrp4/Corin in the present application); and document 3 describes antibodies to human corin (equivalent to Lrp4/Corin in the present application).

#### Claim 6

Based on the descriptions in documents 4 and 5 cited in the international search report, the invention of claim 6 lacks novelty and an inventive step.

Document 4 describes a process for differentiating dopamine-producing neurons from precursor cells using differentiation inducing agents such as retinoic acid, etc.; and document 5 describes a process for differentiating dopamine-producing neurons from precursor cells using sonic hedgehog.

#### Claims 7, 8

Based on the description in Document 4 cited in the international search report, the inventions of claims 7 and 8 lack an inventive step.

Document 4 describes a process for differentiating dopamine-producing neurons from precursor cells using differentiation inducing agents such as retinoic acid, etc., and the differentiation of neurons is monitored using the detection of tyrosine hydroxylase and bc1-2 production. Therefore, the detection of genes and chemical substances associated with differentiation and induction are obvious to persons skilled in the art.

International application No.

### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

PCT/JP2004/000629

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The invention of claim 1 describes a base sequence containing 15 bases associated with a base sequence hybridized under stringent conditions with the base sequence of SEQ ID NO: 1 or 2, but the fact that a polynucleotide isolated from the base sequence of SEQ ID NO: 1 or 2 can be used to detect dopamine-producing neurons is not fully supported by the Description.

The invention of claim to describes an antibody to a polypeptide having a polypeptide of 8 amino acid residues associated with Lrp4/Corin. The fact that this kind of short fragment can detect dopamine-producing neurons is not fully supported by the Description.

International application No.

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

PCT/JP2004/000629

Supplemental Box Relating to Sequence Listing	
Continuation of Box No. 1, item 2:	
<ol> <li>With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this report was established on the basis that of:</li> </ol>	
a. type of material	
a sequence listing	1
table(s) related to the sequence listing	
b. format of material	ļ
in written format	- }
in computer readable form	
c. time of filing/furnishing	
contained in the international application as filed	
filed together with the international application in computer readable form	
furnished subsequently to this Authority for the purpose of search and/or examination	
received by this Authority as an amendment* on	
2. In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been fill or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.	:d
3. Additional comments:	
	ļ
·	
·	
mana yang sa	
·	
* If item 4 in Box No. I applies, the listing and /or table(s) related thereto, which form part of the basis of the report, may be mo	rked
"superseded".	
1	

#### INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/IP2004/000629

INTERNATIONAL INCLIMINANT R	El Olti Oltiliza		FC1/3F2004/000029	
Supplemental Box				
In case the space in any of the preceding boxes Continuation of Box V: Claims 1 and 3-5 The inventions of claims 1 and 3- documents cited in the international s These documents do not state that expressed in dopamine-producing near the art cannot easily conceive of that	5 are novel and earch report. t the Lrp4/Coriu uron proliferation	n identified as SEC	D NO: 1-4 is specifically	1
•				
· -				
i				